SinoMab BioScience (FRA:4VF) GF Score: 19/100 (As of Sep. 10, 2026) — 63% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4VF SinoMab BioScience Ltd FRA:4VF
19 GF Score
Price €0.12
! 2 Warning Signs
View Full Analysis

What is SinoMab BioScience GF Score?

SinoMab BioScience FRA:4VF 19 GF Score is 19 as of Sep. 10, 2026, which is 63% below its 10-year median of 51.00. GuruFocus rates FRA:4VF with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

SinoMab BioScience has the GF Score of 19, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 7/10
2. Profitability Rank : 1/10
3. Growth Rank : 0/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes SinoMab BioScience might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

SinoMab BioScience  (FRA:4VF) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

SinoMab BioScience GF Score Related Terms

FRA:4VF vs VRTX, REGN, MRNA: GF Score Comparison

For the Biotechnology subindustry, SinoMab BioScience's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SinoMab BioScience GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SinoMab BioScience's GF Score distribution charts can be found below:

* The bar in red indicates where SinoMab BioScience's GF Score falls into.


FRA:4VF
19GF Score
SinoMab BioScience Ltd FRA:4VF
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 19 mean?
SinoMab BioScience (FRA:4VF) has a GF Score of 19 as of Sep. 10, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on SinoMab BioScience and its competitors. This is 63% below median its historical median of 51.00. Over the past decade, SinoMab BioScience's GF Score has ranged from 20.00 to 54.00.
Is SinoMab BioScience's GF Score too high?
SinoMab BioScience's current GF Score of 19 is 63% below median its 10-year median of 51.00. Over the past 10 years, this metric has ranged from a low of 20.00 to a high of 54.00. Overall, SinoMab BioScience has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does SinoMab BioScience's GF Score compare to VRTX and REGN?
SinoMab BioScience's GF Score of 19 can be compared against companies in the Biotechnology industry. Historically, SinoMab BioScience's own GF Score has ranged from 20.00 to 54.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on SinoMab BioScience and its competitors. SinoMab BioScience's current GF Score is 19, which is 63% below median its own 10-year median of 51.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SinoMab BioScience stock overvalued right now?
SinoMab BioScience (FRA:4VF) has a current GF Score of 19. The current GF Score is 19, which is 63% below median its 10-year median of 51.00. SinoMab BioScience's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For SinoMab BioScience (FRA:4VF), the current GF Score is 19 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SinoMab BioScience Business Description

Other Exchanges 03681:Hong Kong
Address No. 15 Science Park West Avenue, Units 303 and 305 to 307, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, HKG
SinoMab BioScience Ltd is a biopharmaceutical company focused on the research, development, manufacturing, and commercialisation of therapeutics for the treatment of immunological diseases, mainly monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. In addition, the company possesses other potential first-in-class drug candidates (like SM17, SN1011, SM06, SM09, etc.) some of which are already in the clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases.
19GF Score

Get the complete analysis for FRA:4VF

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.12
Price